Please assess the completion status of the following clinical trial:

Trial Title: Suprathel Versus Xeroform for the Management of Skin Graft Donor Sites

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children 31 days old -17 years old~* Have a burn injury or open wound of any percentage TBSA~* Require a skin graft~Exclusion Criteria:~* allergy to one of the dressings involved in the study,~* burn in close proximity to the donor site,~* the donor site has been harvested in a previous surgery,~* prisoners,~* children under the protection of the department of human services,~* pregnant women,~* those with impaired decision-making capacity.

- Gender: ALL
- Minimum Age: 31 Days
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Suprathel (Type: EXPERIMENTAL): Once hemostasis is obtained, the Suprathel material will be handled with a new pair of sterile gloves. It will be cut so that the material extends 1-2 cm beyond the donor site margins, then applied to the donor site. The Suprathel will be secured with a protective layer of Rylon extending 1-2 cms beyond the margins of the Suprathel. The primary dressing will be covered with cotton gauze (4x4 fluff gauze pads) and wrapped with rolled gauze). The outer dressing will be changed 7-10 days post-op. The Suprathel and Rylon will remain in place until they can be easily peeled off. To facilitate the pain-free and easy removal of the primary Suprathel dressing, practioners will apply Vaseline or lotion to saturate and loosen the material. The patients will be followed on average about once per week in an outpatient clinic until the Suprathel (and Rylon) are removed, but they may continue to be seen until the STSG is fully healed.
- Xeroform (Type: ACTIVE_COMPARATOR): After hemostasis occurs, the Xeroform dressing will be handled with a new pair of sterile gloves and cut so that the material extends 1-2 cm beyond the donor site margins, then applied to the donor site. The primary dressing will be covered with cotton gauze (4x4 fluff gauze pads) and wrapped with rolled gauze (Kerlix). The outer dressing will be changed 7-10 days post-op. The Xeroform will remain in place until it can be easily peeled off. To facilitate the pain-free and easy removal of the Xeroform dressing, practioners may apply Vaseline or lotion to saturate and loosen the material. The patients will be followed on average about once per week in an outpatient clinic until the Xeroform is removed, but they may continue to be seen until the STSG is fully healed.

Based on this trial design, predict the completion outcome and termination type (if applicable).